BioTech
CNTX

Context Therapeutics Gains FDA Fast Track Status For CTIM-76 In Ovarian Cancer

April 02, 2026 — 07:46 am EDT

Written by RTTNews.com for RTTNews->

(RTTNews) - Context Therapeutics Inc. (CNTX) on Thursday said the U.S. Food and Drug Administration has granted Fast Track Designation to its drug candidate CTIM-76 for the treatment of platinum-resistant ovarian cancer in patients who have exhausted standard therapies.

The company said a Phase 1 study of CTIM-76 is currently underway, with interim data expected in June 2026.

Shares of Context Therapeutics rose more than 3% in pre-market trading after closing at $2.65 on Wednesday.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

BioTech
RTTNews
Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.
More articles by this source->

Stocks mentioned

CNTX

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

  • •

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.